(firstQuint)A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients.

 This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study to evaluate the efficacy and safety of TVP-1012 in Japanese participants with early Parkinson's disease.

 The study period will consist of a 28-week trial period.

 The participants who fulfill the inclusion criteria and not meeting any of the exclusion criteria will be enrolled, and randomized in a 1:1 ratio to either the 1 mg of TVP-1012 or the placebo group.

 In each treatment group, participants will receive either 1 mg of TVP-1012 or placebo once daily in a double-blinded manner.

.

 A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients@highlight

The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.

